Roble, Belko & Company, Inc Aeglea Bio Therapeutics, Inc. Call Options Transaction History
Roble, Belko & Company, Inc
- $634 Million
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding AGLE
# of Institutions
1Shares Held
241KCall Options Held
0Put Options Held
0About Aeglea BioTherapeutics, Inc.
- Ticker AGLE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 61,172,500
- Market Cap $1.69B
- Description
- Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy f...